224 related articles for article (PubMed ID: 21920601)
21. Dysplasia has A differential diagnosis: distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors.
Steensma DP
Curr Hematol Malig Rep; 2012 Dec; 7(4):310-20. PubMed ID: 23015360
[TBL] [Abstract][Full Text] [Related]
22. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
23. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathologic evaluation of cytopenic patients with isolated trisomy 8: a detailed comparison between idiopathic cytopenia of unknown significance and low-grade myelodysplastic syndrome.
Petrova-Drus K; Hasserjian R; Pozdnyakova O; Dal Cin P; Mathew S; Margolskee E; Orazi A; Geyer JT
Leuk Lymphoma; 2017 Mar; 58(3):569-577. PubMed ID: 27389864
[TBL] [Abstract][Full Text] [Related]
25. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
26. Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation.
Juopperi TA; Bienzle D; Bernreuter DC; Vernau W; Thrall MA; McManus PM
Vet Pathol; 2011 Jan; 48(1):182-97. PubMed ID: 21139142
[TBL] [Abstract][Full Text] [Related]
27. ICUS/CCUS/CHIP: basics & beyond.
Jain M; Tripathi A
Expert Rev Hematol; 2017 Oct; 10(10):915-920. PubMed ID: 28832236
[TBL] [Abstract][Full Text] [Related]
28. Reduction in multi-lineage and erythroid progenitors distinguishes myelodysplastic syndromes from non-malignant cytopenias.
Vercauteren SM; Bashashati A; Wu D; Brinkman RR; Eaves C; Eaves A; Karsan A
Leuk Res; 2009 Dec; 33(12):1636-42. PubMed ID: 19414193
[TBL] [Abstract][Full Text] [Related]
29. Challenges in Diagnosing Myelodysplastic Syndromes in the Era of Genetic Testing: Proceedings of the 13th Workshop of the European Bone Marrow Working Group.
Hebeda KM; Tzankov A; Boudova L; Saft L; Hasserjian RP; de Boer M; Fend F; Orazi A; Leguit R
Pathobiology; 2019; 86(1):62-75. PubMed ID: 29982244
[TBL] [Abstract][Full Text] [Related]
30. [The myelodysplastic syndrome I. Pathogenesis, clinical symptoms, diagnosis and differential diagnosis].
Hasselbalch HC; Juhl BR; Hansen PB
Ugeskr Laeger; 2002 Jan; 164(4):476-9. PubMed ID: 11838417
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of Flow Cytometry Standardized Using the European LeukemiaNet for Myelodysplastic Syndrome.
Takeuchi A; Imataki O; Kubo H; Kondo A; Seo K; Uemura M; Yamaoka G; Murao K; Takeuchi A
Acta Haematol; 2020; 143(2):140-145. PubMed ID: 31330512
[TBL] [Abstract][Full Text] [Related]
32. Unique ethnic features of
Choi EJ; Cho YU; Hur EH; Jang S; Kim N; Park HS; Lee JH; Lee KH; Kim SH; Hwang SH; Seo EJ; Park CJ; Lee JH
Haematologica; 2022 Feb; 107(2):510-518. PubMed ID: 33626862
[TBL] [Abstract][Full Text] [Related]
33. Clinical implications and genetic features of clonal cytopenia of undetermined significance compared to lower-risk myelodysplastic syndrome.
Choi EJ; Cho YU; Hur EH; Park HS; Choi Y; Lee JH; Lee KH; Kim M; Hwang SH; Jang S; Park CJ; Seo EJ; Lee JH
Br J Haematol; 2022 Aug; 198(4):703-712. PubMed ID: 35612271
[TBL] [Abstract][Full Text] [Related]
34. Diagnosis of secondary myelodysplastic syndromes (MDS) following autologous transplantation should not be based only on morphological criteria used for diagnosis of de novo MDS.
Amigo ML; del Cañizo MC; Rios A; Garcia MA; Caballero MD; Martin A; Bermejo N; Vilches P; San Miguel JF
Bone Marrow Transplant; 1999 May; 23(10):997-1002. PubMed ID: 10373064
[TBL] [Abstract][Full Text] [Related]
35. p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.
Kitagawa M; Yoshida S; Kuwata T; Tanizawa T; Kamiyama R
Am J Pathol; 1994 Aug; 145(2):338-44. PubMed ID: 8053492
[TBL] [Abstract][Full Text] [Related]
36. [Mixed myelodysplastic and myeloproliferative syndromes].
Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
[TBL] [Abstract][Full Text] [Related]
37. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
[TBL] [Abstract][Full Text] [Related]
38. Classification and prognostic evaluation of myelodysplastic syndromes.
Cazzola M; Della Porta MG; Travaglino E; Malcovati L
Semin Oncol; 2011 Oct; 38(5):627-34. PubMed ID: 21943669
[TBL] [Abstract][Full Text] [Related]
39. [Myelodysplastic syndromes].
Solary E; Fontenay M
Rev Prat; 2010 Dec; 60(10):1408-9, 1412. PubMed ID: 21425540
[TBL] [Abstract][Full Text] [Related]
40. MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance.
Kwok B; Hall JM; Witte JS; Xu Y; Reddy P; Lin K; Flamholz R; Dabbas B; Yung A; Al-Hafidh J; Balmert E; Vaupel C; El Hader C; McGinniss MJ; Nahas SA; Kines J; Bejar R
Blood; 2015 Nov; 126(21):2355-61. PubMed ID: 26429975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
